SG11201906616VA - Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants - Google Patents

Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants

Info

Publication number
SG11201906616VA
SG11201906616VA SG11201906616VA SG11201906616VA SG11201906616VA SG 11201906616V A SG11201906616V A SG 11201906616VA SG 11201906616V A SG11201906616V A SG 11201906616VA SG 11201906616V A SG11201906616V A SG 11201906616VA SG 11201906616V A SG11201906616V A SG 11201906616VA
Authority
SG
Singapore
Prior art keywords
international
nasal
composition
silicon dioxide
air pollutants
Prior art date
Application number
SG11201906616VA
Inventor
Claudia Mattern
Original Assignee
M et P Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M et P Pharma AG filed Critical M et P Pharma AG
Publication of SG11201906616VA publication Critical patent/SG11201906616VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIPO I PCT 0111111010 0111 °nolo o1111 mil niou oimIE (10) International Publication Number WO 2018/134783 Al (2017.01) (2006.01) (2006.01) (2006.01) (51) International Patent Classification: A61K 33/00 (2006.01) A61K 47/44 A61K 9/00 (2006.01) A61P 39/00 A61K 47/02 (2006.01) A61P 37/08 A61K 47/14 (2017.01) A61P 29/00 A61K 9/06 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/IB2018/050349 (22) International Filing Date: 19 January 2018 (19.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/448,556 20 January 2017 (20.01.2017) US 62/517,369 09 June 2017 (09.06.2017) US (71) Applicant: M ET P PHARMA AG [CH/CH]; Schynweg 7, P.O. Box 138, 6376 Emmetten (CH). (72) Inventor: MATTERN, Claudia; c/o M et P Pharma AG, Schynweg 7, P.O. Box 138, 6376 Emmetten (CH). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Published: — with international search report (Art. 21(3)) — in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE (54) Title: NASAL PHARMACEUTICAL COMPOSITIONS FOR REDUCING THE RISKS OF EXPOSURE TO AIR POLLUTAN- TS (57) : Described herein are methods for reducing the risks of exposure to air pollutants, comprising nasally administering to a subject in need thereof a composition that counteracts the effects of one or more air pollutants, wherein the composition is adapted for nasal administration. In some embodiments the composition comprisees an agent that binds to one or more air pollu- tants, wherein the agent comprises one or both of nonporous silicon dioxide and porous silicon dioxide and/or the composition provides a physical barrier between one or more air pollutants and internal nasal surfaces. Also described herein are nasal compositions comprising an agent com- prising one or both of nonporous silicon dioxide and porous silicon dioxide, a lipophilic or partly lipophilic vehicle, and a surfactant, wherein the composition is adapted for nasal administration. Also described herein are methods of making and using nasal pharmaceutical compositions. W O 20 18/ 13 47 83 Al FIG. 10B
SG11201906616VA 2017-01-20 2018-01-19 Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants SG11201906616VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448556P 2017-01-20 2017-01-20
US201762517369P 2017-06-09 2017-06-09
PCT/IB2018/050349 WO2018134783A1 (en) 2017-01-20 2018-01-19 Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants

Publications (1)

Publication Number Publication Date
SG11201906616VA true SG11201906616VA (en) 2019-08-27

Family

ID=61094560

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906616VA SG11201906616VA (en) 2017-01-20 2018-01-19 Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants

Country Status (11)

Country Link
US (1) US10729646B2 (en)
EP (1) EP3570848B1 (en)
KR (1) KR20190109452A (en)
CN (1) CN110461340A (en)
CA (1) CA3050361A1 (en)
ES (1) ES2948282T3 (en)
HU (1) HUE063346T2 (en)
MX (2) MX2019008656A (en)
RU (1) RU2019123307A (en)
SG (1) SG11201906616VA (en)
WO (1) WO2018134783A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026041A1 (en) 2016-06-03 2017-12-07 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2019138356A1 (en) 2018-01-11 2019-07-18 M et P Pharma AG Treatment of demyelinating diseases
KR20210028409A (en) 2019-09-04 2021-03-12 엘지디스플레이 주식회사 Organic compounds having improved luminsecent properties, organic light emitting diode and organic light emitting device including the compounds
US20210275989A1 (en) * 2020-03-05 2021-09-09 Performance Labs PTE. LTD. Functional materials and devices for reducing toxic pollutants
AU2021380914A1 (en) * 2020-11-19 2023-06-22 Acousia Therapeutics Gmbh Non-aqueous gel composition
CN114653172B (en) * 2022-03-15 2023-11-14 江苏理工学院 Synergistic removal of VOCs and Hg 0 Is a method of (2)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546882A (en) 1983-02-07 1985-10-15 American Can Company Package having oil-containing product
US5002597A (en) * 1989-04-03 1991-03-26 Invent Ag Aerodynamic filter
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19701912C1 (en) 1997-01-10 1998-05-14 Jenapharm Gmbh Implant for controlled drug release
DE10064950A1 (en) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropic nasal spray
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
ATE319426T1 (en) 2003-11-11 2006-03-15 Mattern Udo NASAL FORMULATION WITH CONTROLLED RELEASE OF SEXUAL HORMONES
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
US20070077309A1 (en) 2005-09-30 2007-04-05 Wong Patrick S Banded controlled release nanoparticle active agent formulation dosage forms and methods
AU2007304471B2 (en) 2006-10-04 2012-09-06 M & P Patent Aktiengesellschaft Controlled release delivery system for nasal application of neurotransmitters
US8258137B2 (en) 2008-01-29 2012-09-04 Katholieke Universiteit Leuven Process for release of biologically active species from mesoporous oxide systems
KR20170096241A (en) 2008-09-23 2017-08-23 라보라토리 스킨 케어, 인크. Active agent loaded uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same
JP2010083834A (en) * 2008-10-01 2010-04-15 Naris Cosmetics Co Ltd Allergen inactivator and cosmetic product containing the same
WO2010050897A1 (en) 2008-10-28 2010-05-06 Agency For Science, Technology And Research Mesoporous material excipients for poorly aqueous soluble ingredients
JP6562630B2 (en) * 2011-05-13 2019-08-21 エーセラス ファーマシューティカルズ コーポレーション Low dosage concentration testosterone gel formulation for nasal administration and its use to treat aorgasmia or hyposexual desire disorder
US20130040922A1 (en) * 2011-05-13 2013-02-14 Trimel Pharmaceuticals Corporation Intranasal 0.45% and 0.48% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
CA2836405C (en) * 2011-05-15 2021-09-07 Trimel Biopharma Srl Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
KR102100271B1 (en) * 2012-02-27 2020-04-14 바이엘 뉴질랜드 리미티드 Controlled release compositions and their methods of use
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
US20150290217A1 (en) 2012-11-21 2015-10-15 Trimel Biopharma Srl Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
EP3065717A1 (en) 2013-11-04 2016-09-14 Biopharmx, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
EP3193836A1 (en) 2014-09-15 2017-07-26 PharmaSol GmbH Active-loaded particulate materials for topical administration
KR20180032644A (en) * 2015-08-04 2018-03-30 인큐팜 그룹 센디리안 버하드 Nose composition
EP3347124A1 (en) * 2015-09-09 2018-07-18 King Abdullah University Of Science And Technology Functionalized sio2 microspheres for extracting oil from produced water
CA3026041A1 (en) 2016-06-03 2017-12-07 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient

Also Published As

Publication number Publication date
EP3570848A1 (en) 2019-11-27
KR20190109452A (en) 2019-09-25
CA3050361A1 (en) 2018-07-26
EP3570848C0 (en) 2023-06-07
MX2022006529A (en) 2022-07-11
HUE063346T2 (en) 2024-01-28
US10729646B2 (en) 2020-08-04
ES2948282T3 (en) 2023-09-07
RU2019123307A (en) 2021-02-20
WO2018134783A1 (en) 2018-07-26
MX2019008656A (en) 2019-11-21
US20180296472A1 (en) 2018-10-18
EP3570848B1 (en) 2023-06-07
RU2019123307A3 (en) 2021-05-24
CN110461340A (en) 2019-11-15

Similar Documents

Publication Publication Date Title
SG11201906616VA (en) Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201810116VA (en) Exosomes comprising therapeutic polypeptides
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201907023UA (en) Method of reducing neutropenia
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201810872UA (en) Composition and method for reducing neutropenia
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201407801VA (en) Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
SG11201809882XA (en) Pharmaceutical combinations for treating cancer